Cheifetz / Feuerstein Treatment of Inflammatory Bowel Disease with Biologics

1. Auflage 2018
ISBN: 978-3-319-60276-9
Verlag: Springer International Publishing
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 335 Seiten, eBook

This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field,  Treatment of Inflammatory Bowel Disease with Biologics  is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Cheifetz, Adam S.

Feuerstein, Joseph D.

Inhaltsverzeichnis

Mechanism of Action and Pharmacokinetics of Biologics.- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis.- Anti-tumor Necrosis Factor Agents in Crohn’s Disease.- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease.- Use of Biologics in the Postoperative Management of Crohn’s Disease.- Biologics in Pregnancy and Breastfeeding.- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease.- Therapeutic Drug Monitoring of Biologic Agents.- Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks.- Cessation of Biologics – Can it be Done?.- Biologic Therapy in Pediatric Inflammatory Bowel Disease.- Infectious Complications of Biologics.- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy.- Non-infectious and Non-malignant Complications of Biologics.- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances.- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications.- Novel Agents in Inflammatory Bowel Disease.- Quality, Safety, and Practical Considerations of Using Biologic Therapies.

Über Autor(innen)

Adam S. Cheifetz, MDBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USAJoseph D. Feuerstein, MDBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA